Browse studies

Find your next paid study

1 recruiting study matching your filters

Randomized Phase II Study of Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) in Patients With ER+/HER2- Advanced or Metastatic Breast Cancer With Prior Exposure to a CKD4/6 Inhibitor

Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negat…

Estrogen-receptor-positive Breast CancerHER2/Neu-Negative Breast CancerAdvanced Breast Cancerv+1 more

Northwestern UniversityNCT06062498